UPMC Enterprises’ Post

How can we help drugs to cross the blood-brain barrier to more effectively treat neurological diseases? Through its collaborative model, the Wyss' Brain Targeting Program is discovering and developing new, safe brain transport shuttles and effective ways to test them. Both are now available for non-exclusive licensing. #BrainTargetingProgram #NeurodegenerativeDisease #DrugDelivery #Therapeutics #BrainResearch https://lnkd.in/eD53bvk4

Interesting therapeutic approach from UCLA for neurodegenerative diseases (dementia/Alzheimer's) that works differently from the recently FDA-approved antibodies (Lecanemab, Donanemab) which target amyloid beta plaques in the brain. This approach involves a therapeutic small molecule that enhances γ-oscillations (30 to 120 Hz) and improves cognition and memory in mice by blocking the GABA-A receptor. This receptor typically inhibits the interneurons that generate γ-oscillations. Looking forward to seeing future clinical trials, if any are planned. FUN FACT: A frequency of 40 Hz oscillating waves is similar to the frequency of a cat's purr. https://lnkd.in/eJAq5Jxx

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖

𝗦𝗶𝗻𝗴𝗹𝗲 𝗮𝗻𝗱 𝗠𝘂𝗹𝘁𝗶𝘁𝗮𝗿𝗴𝗲𝘁 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗮𝗻𝗱 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻: 𝗨𝗽-𝘁𝗼-𝗗𝗮𝘁𝗲 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 𝗳𝗼𝗿 𝗕𝗿𝗮𝗶𝗻 𝗗𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 This review summarizes the recent findings on the development of different types of single and multitarget nanoparticles for disease detection and drug delivery to the brain, focusing on promising active principles encapsulated and nanoparticle surface modification and functionalization. Functionalized nanoparticles have emerged as promising tools for the diagnosis and treatment of brain disorders, offering a novel approach to addressing complex neurological challenges. 

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖

They write: This study reports the discovery of a small molecule that prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site. A machine learning approach was used to screen for small molecules targeting the AMPA receptor GluA2 subunit. The lead candidate has potent effects in restoring neurological function and myelination while reducing the immune response in experimental autoimmune encephalitis and cuprizone MS mouse models without affecting basal neurotransmission or learning and memory. These findings facilitate development of a treatment for MS with a different mechanism of action than current immune modulatory drugs and avoids important off-target effects of glutamate receptor antagonists.

Delve into the world of #neurological biomarkers—NfL, p-Tau 181, p-Tau 217, GFAP—to gain insight into how these biomarkers are leading to improved diagnostics, therapies, and clinical trials for disorders like #Alzheimers and Parkinson’s. 📖